Now processing ... 
 Now searching ... 
 Now loading ... 

MASHの肝組織像(HE染色)

肝細胞の風船様変性、中~大滴性脂肪滴の沈着、炎症性細胞浸潤、肝細胞周囲の線維化を認める。
出典
img
1: 西原利治先生ご提供

MASLDの肝疾患関連死

参考文献:
  1. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021;385:1559-1569.
出典
img
1: 著者提供

肝線維化と肝臓関連イベントリスクの関連性

出典
imgimg
1: Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
著者: Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
雑誌名: Clin Gastroenterol Hepatol. 2023 Feb;21(2):370-379. doi: 10.1016/j.cgh.2022.01.002. Epub 2022 Jan 17.
Abstract/Text: BACKGROUND & AIMS: There are no detailed reports of clinical outcomes in Asian patients with nonalcoholic fatty liver disease (NAFLD) who undergo liver biopsy. We aimed to investigate the clinical outcomes of a large cohort of Asian patients with biopsy-proven NAFLD and evaluate the specific effects of nonalcoholic steatohepatitis and fibrosis stage.
METHODS: This multicenter registry-based retrospective cohort study, called the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) in Asia, included 1398 patients.
RESULTS: The median follow-up period was 4.6 years (range, 0.3-21.6 years), representing a total of 8874 person-years of follow-up. During that time, 47 patients died, and 1 patient underwent orthotopic liver transplantation. The leading cause of death was nonhepatic cancer (n = 10). The leading causes of liver-related death were liver failure (n = 9), hepatocellular carcinoma (HCC) (n = 8), and cholangiocellular carcinoma (n = 4). During follow-up, 37 patients developed HCC, 31 developed cardiovascular disease, and 68 developed nonhepatic cancer (mainly breast, stomach, and colon/rectum). Among our cohort of patients with NAFLD, liver-specific mortality was 2.34/1000 person-years (95% confidence interval [CI], 1.52-3.58), overall mortality was 5.34/1000 person-years (95% CI, 4.02-7.08), and HCC incidence was 4.17/1000 person-years (95% CI, 3.02-5.75). Liver fibrosis was independently associated with liver-related events but not overall mortality.
CONCLUSIONS: Liver-related mortality was the leading cause of mortality in Asian patients with biopsy-confirmed NAFLD. Although fibrosis stage was independently associated with liver-related events, it was not associated with overall mortality after adjusting for confounders, such as histologic features of steatohepatitis.

Copyright © 2023. Published by Elsevier Inc.
Clin Gastroenterol Hepatol. 2023 Feb;21(2):370-379. doi: 10.1016/j.cgh...

MASHの肝組織像(HE染色)

肝細胞の風船様変性、中~大滴性脂肪滴の沈着、炎症性細胞浸潤、肝細胞周囲の線維化を認める。
出典
img
1: 西原利治先生ご提供

MASLD/MASH診断フローチャート

注:HCV抗体陽性例は、HCV-RNAを測定してC型慢性肝炎・肝硬変を鑑別する。
注:MASLD/MASHと自己免疫性肝炎の鑑別は、困難なことがある。
 
MASLDでは肥満症例が多く、インスリン抵抗性を基盤とした糖尿病、高血圧、脂質異常症などのメタボリックシンドロームのリスクファクターを認める例が多い。MASHと単純性脂肪肝との判別は肝生検所見に基づく。
出典
img
1: 日本肝臓学会 編「NASH・NAFLDの診療ガイド2015」2015年,P32,文光堂(一部改変)

肝線維化進展例の絞り込みフローチャート

出典
img
1: 「日本消化器病学会,日本肝臓学会編:NAFLD/NASH診療ガイドライン2020,改訂第2版,p.xx,2020,南江堂」より許諾を得て転載.